Advertisement

 

 

Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418).

Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418).
Author Information (click to view)

Kim H, Park W, Yu JI, Choi DH, Huh SJ, Kim YJ, Lee ES, Lee KS, Kang HS, Park IH, Shin KH, Kim K, Park KR, Kim YB, Ahn SJ, Lee JH, Kim JH, Chun M, Lee HS, Kim JS, Lee JY,


Kim H, Park W, Yu JI, Choi DH, Huh SJ, Kim YJ, Lee ES, Lee KS, Kang HS, Park IH, Shin KH, Kim K, Park KR, Kim YB, Ahn SJ, Lee JH, Kim JH, Chun M, Lee HS, Kim JS, Lee JY, (click to view)

Kim H, Park W, Yu JI, Choi DH, Huh SJ, Kim YJ, Lee ES, Lee KS, Kang HS, Park IH, Shin KH, Kim K, Park KR, Kim YB, Ahn SJ, Lee JH, Kim JH, Chun M, Lee HS, Kim JS, Lee JY,

Advertisement

Oncotarget 2016 Oct 25() doi 10.18632/oncotarget.12882
Abstract
BACKGROUND AND PURPOSE
This study was performed to determine optimal radiation dose in pN1 breast cancer patients who received breast conserving surgery (BCS) and anthracycline plus taxane (AT)-based chemotherapy.  Materials and Methods: Retrospective chart reviews were performed in 1,147 patients who were treated between January 2006 and December 2010. The impact of radiation dose on treatment outcomes was evaluated.

RESULTS
Median follow-up time was 66 months. The 5-year rate of disease-free survival (DFS) was 93.2%. Larger tumor size (> 20 mm), positive lymphovascular invasion, high histologic grade, and high ratio of positive nodes (> 0.1) were significantly associated with inferior DFS. By using the 4 factors related to DFS, patients were categorized into high-risk (with ≥ 3 factors) and low-risk (with < 3 factors) groups. In the high-risk group, higher radiation dose (> 60.3 GyEQD2) was significantly associated with better DFS than the lower dose (≤ 60.3 GyEQD2). However, the radiation dose did not impact DFS in the low-risk group.

CONCLUSIONS
Dosing of radiation affects the outcome of post-BCS radiotherapy in pN1 breast cancer. Doses of over 60.3 GyEQD2 were associated with better outcome in the high-risk patients.

Submit a Comment

Your email address will not be published. Required fields are marked *

one + twelve =

[ HIDE/SHOW ]